XML 66 R55.htm IDEA: XBRL DOCUMENT
v3.24.3

Related Parties Transactions (Details) - Schedule of Due from Related Parties - Current - USD ($) | Sep. 30, 2024 | Dec. 31, 2023
--- | --- | ---
Rgene [Member] |  |  |
Related Parties Transactions (Details) - Schedule of Due from Related Parties - Current [Line Items] |  |  |
Due from related-party - Current | [1] | $ 559,489 | $ 541,486
BioFirst [Member] |  |  |
Related Parties Transactions (Details) - Schedule of Due from Related Parties - Current [Line Items] |  |  |
Due from related-party - Current | [2] | 644,873 | 206,087
Related Party [Member] |  |  |
Related Parties Transactions (Details) - Schedule of Due from Related Parties - Current [Line Items] |  |  |
Due from related-party - Current |  | 1,204,362 | 747,573
Due from related parties - Non-Current |  | 964,134 | 953,499
Less: allowance for expected credit losses accounts |  | (839,983) | (839,983)
Net |  | 124,151 | 113,516
BioFirst (Australia) [Member] |  |  |
Related Parties Transactions (Details) - Schedule of Due from Related Parties - Current [Line Items] |  |  |
Due from related parties - Non-Current | [3] | 839,983 | 839,983
BioHopeKing Corporation [Member] |  |  |
Related Parties Transactions (Details) - Schedule of Due from Related Parties - Current [Line Items] |  |  |
Due from related parties - Non-Current | [4] | $ 124,151 | $ 113,516
[1] | On June 16, 2022, the Company entered into a one-year convertible loan with Rgene, with a principal amount of $1,000,000 to Rgene which bears interest at 5% per annum for the use of working capital that, if fully converted, would result in ABVC owning an additional 6.4% of Rgene. The Company may convert the Note at any time into shares of Rgene’s common stock at either (i) a fixed conversion price equal to $1.00 per share or (ii) 20% discount of the stock price of the then most recent offering, whichever is lower; the conversion price is subject to adjustment as set forth in the Note. The Note includes standard events of default, as well as a cross default provision pursuant to which a breach of the Service Agreement will trigger an event of default under the convertible note if not cured after 5 business days of written notice regarding the breach is provided.As of September 30, 2024 and December 31, 2023, the outstanding loan balance were $506,216 and $500,000, respectively; and accrued interest was $51,319 and $38,819, respectively. The Company expects to receive the repayment within next 12 months once Rgene receives the licensing fees from OncoX.As of September 30, 2024 and December 31, 2023, the Company has other receivables amounted $1,954 and $2,667, respectively, from Rgene due to daily operations.
[2] | On December 31, 2023, BioLite Taiwan entered into a loan agreement with BioFirst, with a principal amount of $348,779 (NTD 11,072,360) to BioFirst which bears interest at 12% per annum for the use of working capital. During the period ended September 30, 2024, the Company entered into another loan agreement with BioFirst, with a principal amount of $359,289 (NTD 11,406,000) to BioFirst which bears interest at 12% per annum for the use of working capital. As of September 30, 2024 and December 31, 2023, the outstanding loan balance were $606,323 (NTD 19,248,360) and $206,087 (NTD 6,302,360), respectively; accrued interest was $37,520 and $0, respectively. The Company has received $100,076 (NTD 3,230,000) repayment and expects to receive other repayment within next 12 months. As of September 30, 2024 and December 31, 2023, the Company has other receivables from BioFirst amounted $1,030 and $0, respectively, due to daily operations.
[3] | The balances mainly represent advances to BioFirst (Australia) for research and development purposes. The business conditions of BioFirst (Australia) deteriorated and, as a result, the Company recognized expected credit losses of $839,983 for the year ended December 31, 2023.
[4] | On February 24, 2015, BioLite Taiwan and BioHopeKing Corporation (the “BHK”) entered into a co-development agreement, (the “BHK Co-Development Agreement”, see Note 3). The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK. As of September 30, 2024 and December 31, 2023, due from BHK was $124,151 and $113,516, respectively.

X
- References No definition available. + Details
Name: | abvc_RelatedPartiesTransactionsDetailsScheduleofDuefromRelatedPartiesCurrentLineItems
Namespace Prefix: | abvc_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, after allowance for credit loss, of receivable classified as other and noncurrent. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of allowance for credit loss on receivable classified as other and noncurrent. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_OtherReceivableAllowanceForCreditLossNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount, before allowance for credit loss, of receivable classified as other and noncurrent. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1 + Details
Name: | us-gaap_OtherReceivableBeforeAllowanceForCreditLossNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer. + References No definition available. + Details
Name: | us-gaap_OtherReceivablesNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=abvc_RgeneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstAustraliaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=abvc_BioHopeKingCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |